NOMATEN ONLINE-SEMINAR June 6: Antibody-based radiopharmaceuticals

Date
Date 2
Place
Online: https://www.gotomeet.me/NCBJmeetings/nomaten-seminar

NOMATEN ONLINE-SEMINAR

online: https://www.gotomeet.me/NCBJmeetings/nomaten-seminar

Tuesday, JUNE 6th  2023 13:00 CET

Antibody-based radiopharmaceuticals.

Dr. Charles TRUILLET
CEA / Institut des sciences du vivant Frédéric Joliot / SHFJ (Service hospitalier Frédéric Joliot) / BIOMAPS, France.

 

Abstract:

Antibody-based radiolabeled molecules to in vivo diagnose, follow and predict the tumor evolution and associated treatment efficacy (diagnosis, imaging purposes) and to kill tumor cells with the association of tumoricidal isotope (treatment). Antibodies and its derivatives as diagnostic tools or as therapeutic platforms if associated with specific radioisotope, or as a theranostic platforms by associating both aspects (diagnostic, treatment).

Bio:

Charles Truillet (PhD, HDR) is an experienced chemical biologist with a deep interest and knowledge in theranostic strategy. The overall goal of his research is to develop new theranostic methodologies for the detection and treatment of cancer, with a principal emphasis on the relation between the immune system and tumor cells. I received my PhD in nanosciences for biomedical application in 2013. During this graduate work at Université Claude Bernard Lyon 1, he has largely contributed to the development and characterization of a new ultrasmall nanoplatform (termed AGuIX) that was transfered into clinical application as a radio-enhancer agent for radiotherapy (currently in phase 3). In 2014, Charles gas joined the Evans’s lab as a post-doc at UCSF (University of California San Francisco) looking to build upon his training by focusing more systematically on the biology of important tumor signaling pathway drivers that regulate the uptake of imaging agents. He was the first to measure PD-L1 expression in vivo thanks to an innovative radiolabeled antibody in preclinical model. He has accepted a faculty position as a CEA researcher in the field of molecular imaging research in 2017. The purpose of this position was to build a group focused on imaging the immune system and the tumor cells. He is currently leading the ONCO group (6 researchers and 4 technicians) from BioMaps in the thematic of immunoPET imaging, gathering ligand based-antibody and PET imaging. He successfully transferred several preclinical ligands and methods, from preclinical to clinical applications. His research topics include a strong collaboration between biologists, pharmacologists, physicists, chemists and clinicians. Charles Truillet received several funding supports from INCA and ANR.

 

Dr. Charles TRUILLET

Galeria
Dr. Charles TRUILLET

Tags



This project has received funding from the European Union Horizon 2020 research and innovation
programme under grant agreement No 857470 and from European Regional Development Fund
via Foundation for Polish Science International Research Agenda PLUS programme grant
No MAB PLUS/2018/8.
Poland
The project is co-financed from the state budget within the framework of the undertaking of the Minister of Science and Higher Education "Support for the activities of Centers of Excellence established under Horizon 2020".

Grant: 5 143 237,70 EUR
Total value: 29 971 365,00 EUR
Date of signing the funding agreement: December 2023

The purpose of the undertaking is to support entities of the higher education and science system that have received funding from the European Union budget in the competition H2020-WIDESPREAD-2018-2020/WIDESPREAD-01-2018-2019: Teaming Phase 2. in the preparation, implementation and updating of activities, maintenance of material resources necessary for carrying out activities, acquisition and modernization of scientific and research apparatus, maintenance and development of personnel potential necessary for the implementation of activities, and dissemination of the results of scientific activities.